Jabbour Samer, Ravid Shmuel, Lown Bernard
Faculties of Health Sciences and Medicine, American University of Beirut, Beirut, Lebanon.
Curr Control Trials Cardiovasc Med. 2004 Mar 29;5(1):2. doi: 10.1186/1468-6708-5-2.
Trials in the 1990s demonstrated that medical therapy is as effective as invasive therapies for treating single-vessel coronary disease. Yet more recent studies enrolling patients with this condition have focused on evaluating only invasive approaches, namely, stenting versus coronary artery bypass surgery. Several ethical and scientific questions remain unanswered regarding the conduct of these later trials. Were they justified? Why wasn't a medical therapy arm included? Were subjects informed about the availability of medical therapy as an equivalent option? Was optimized medical therapy given prior to randomization? The absence of clear answers to these questions raises the possibility of serious bias in favor of invasive interventions. Considering that medical therapy is underutilized in patients with coronary disease, efforts should focus more on increasing utilization of medical therapy and proper selection of noninvasive interventions.
20世纪90年代的试验表明,药物治疗在治疗单支冠状动脉疾病方面与侵入性治疗同样有效。然而,最近纳入此类患者的研究仅侧重于评估侵入性方法,即支架置入术与冠状动脉搭桥手术。关于这些后期试验的开展,仍有几个伦理和科学问题未得到解答。这些试验合理吗?为什么没有设立药物治疗组?受试者是否被告知有药物治疗这一等效选择?随机分组前是否给予了优化的药物治疗?这些问题缺乏明确答案,增加了偏向侵入性干预的严重偏差的可能性。鉴于冠状动脉疾病患者对药物治疗的利用不足,应更多地致力于提高药物治疗的利用率以及正确选择非侵入性干预措施。